Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$239.05 USD

239.05
718,021

+4.67 (1.99%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $239.04 -0.01 (0.00%) 5:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks News

LabCorp (LH) Gains As Market Dips: What You Should Know

LabCorp (LH) closed the most recent trading day at $184.33, moving +0.51% from the previous trading session.

Urmimala Biswas headshot

Is Another Great Depression Imminent or Is it Just a Myth?

Asian countries have already shown clear signs of major economic recession.

Thermo Fisher Expands Lab Plastic Making for Coronavirus Support

Thermo Fisher (TMO) consumables already support critical COVID-19 work and include sample collection vials and lab essentials.

LabCorp (LH) Gains But Lags Market: What You Should Know

In the latest trading session, LabCorp (LH) closed at $183.13, marking a +0.91% move from the previous day.

LabCorp (LH) Stock Moves -1.24%: What You Should Know

LabCorp (LH) closed at $174.72 in the latest trading session, marking a -1.24% move from the prior day.

LabCorp (LH) Outpaces Stock Market Gains: What You Should Know

LabCorp (LH) closed at $177.41 in the latest trading session, marking a +1.81% move from the prior day.

Why Is LabCorp (LH) Down 7.9% Since Last Earnings Report?

LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LabCorp (LH) Banks on Covance Amid Testing Volume Pressure

LabCorp's (LH) COVID-19 related research too has been progressing well.

Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines

Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.

Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline

Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.

CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top

CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.

Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates

Merit Medical (MMSI) reported a drop in revenues at every key operating segment in Q2.

Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise

Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Baxter (BAX) Earnings and Revenues Miss Estimates in Q2

Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.

Cerner (CERN) Q2 Earnings Surpass Estimates, Revenues Miss

Cerner (CERN) second-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in margins.

Boston Scientific (BSX) Q2 Earnings Top, Margins Decline

This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.

Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2

Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.

Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down

Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.

LabCorp (LH) Hits 52-Week High, Can the Run Continue?

LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline

LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.

Is Laboratory Corporation of America Holdings (LH) Outperforming Other Medical Stocks This Year?

Is (LH) Outperforming Other Medical Stocks This Year?

LabCorp (LH) Q2 Earnings and Revenues Top Estimates

LabCorp (LH) delivered earnings and revenue surprises of 229.49% and 14.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Delayed Orders Hurt Ekso Bionics (EKSO) Q2 Earnings?

Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.

Zynex (ZYXI) to Report Q2 Earnings: What's in the Cards?

Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.

Why Earnings Season Could Be Great for LabCorp (LH)

LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.